GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome
05. Januar 2022 08:00 ET
|
Ultragenyx Pharmaceutical Inc.; GeneTx Biotherapeutics LLC
SARASOTA, Fla. and NOVATO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102,...
GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala
01. Dezember 2021 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
SARASOTA, Fla. and NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102,...